SCHEMBL7146459

SCHEMBL7146459

O=Cc1cc(OCCc2ccccc2)ccc1OCCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.57
ALOX5 P09917 2/20 0.57
PPARG P37231 2/20 0.57
MAOA P21397 6/20 0.51
MAOB P27338 6/20 0.51
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
FFAR1 O14842 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
LTA4H P09960 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148350 0.92 PTGES (0.53) PTGESALOX5PPARGMAOAMAOB
SCHEMBL9077437 0.90 CYP11B1 (0.54) PTGESALOX5PPARGRAB9AALDH1A1
SCHEMBL7143453 0.87 PTGES (0.49) PTGESALOX5PPARGMAOAMAOB
SCHEMBL12419696 0.85 CA12 (0.52) PTGESALOX5PPARGMAOAMAOB
SCHEMBL9074689 0.83 MEN1 (0.54) MEN1KMT2AALDH1A1HPGDHTT
SCHEMBL8730471 0.83 PTGDR2 (0.60) PTGESALOX5PPARGMEN1KMT2A
SCHEMBL3615463 0.83 MAOB (0.58) ALOX5MAOAMAOBRAB9ANPC1
SCHEMBL1129280 0.82 PTGES (0.50) PTGESALOX5PPARGMAOAMAOB
SCHEMBL9077420 0.82 ALDH1A1 (0.58) PTGESALOX5PPARGMAOAMAOB
SCHEMBL1299482 0.82 HPGD (0.60) MAOAMAOBRAB9ANPC1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA PTGES 1214/4885ALOX5 2017/4885PPARG 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.